Clinical trial · Interventional
Bioavailability and Effectiveness of Transdermally Administered Morphine
NCT00125684CI-TRIAL-00006077completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| morphine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- detectable morphine levels in serum
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Chronic cancer pain * Minimum baseline pain of 3/10 * No change in medications over 3 days prior to study period * Ability to give informed consent * Willingness to undergo repeated blood sampling Exclusion Criteria: * Use of morphine or codeine in 3 days prior to study * Known sensitivity to morphine * Prior anaphylactic reaction to any opioid * Clinically significant anemia
References
Publications (0)
Data not yet available
No reference posted for this study.